aDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD;

bCentre for the AIDS Programme of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa;

cSAMRC-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa;

dPerinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa;

eUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe;

fMakerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Kampala, Uganda;

gCentre for the AIDS Programme of Research in South Africa (CAPRISA), Umlazi Clinical Research Site, University of Kwazulu-Natal, Durban, South Africa;

hUniversity of Kwazulu-Natal, Department of Family Medicine, Durban, South Africa;

iJohns Hopkins Research Project, Kamuzu University of Health Sciences, Blantyre, Malawi;

jUniversity of North Carolina Project-Malawi, Lilongwe, Malawi;

kDepartment of Obstetrics and Gynecology, University of North Carolina, Chapel-Hill, NC;

lCenter for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston MA; and

mDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA.

Correspondence to: Taha E. Taha, MBBS, PhD, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Suite E7132-A, Baltimore, MD 21205 (e-mail: [email protected]).

Presented at the 24th International AIDS Society (IAS) Conference in Montreal, Canada July 24–August 3, 2022.

The PROMOTE study was funded by the President's Emergency Plan for AIDS Relief (PEPFAR) through DAIDS/NIAID/NIH grants to each of the following Clinical Trials Units (CTUs): JHU-Uganda CTU Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Grant # UM1 AI069530-11; The Johns Hopkins University-Blantyre Clinical Trials Unit, Grant # UM1AI069518-12; The University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit, Grant # 5UM1AI069423-12; University of Zimbabwe College of Health Sciences Clinical Trials Research Center, Grant # 5UM1AI069436-12; PHRU KARABELO Clinical Trials Unit for NIAID Networks Grant # 5UM1AI069453; Clinical Trials Unit for AIDS/Tuberculosis Prevention and Treatment—Grant Number: 5 UM1AI069469-11; and CAPRISA Clinical Trials Unit for AIDS/Tuberculosis Prevention and Treatment, Grant # 5UM1 AI069469.

The authors have no funding or conflicts of interest to disclose.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jaids.com).